期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Haemodynamic and renal effects of tadalafil in patients with cirrhosis

Haemodynamic and renal effects of tadalafil in patients with cirrhosis
下载PDF
导出
摘要 A recent report introduced the phosphodiesterase-5 inhibition by vardenafil as a novel treatment of portal hypertension in patients with cirrhosis.In the herein presented"letter to the editor",the administration of tadalafil did not influence portal haemodynamics but impaired systemic haemodynamics in patients with cirrhosis.Our observations concur with the results of a report in a previous issue of World Journal of Gastroenterology(October 2008).Moreover,tadalafil adversely affected renal function in patients with decompensated liver disease. A recent report introduced the phosphodiesterase-5 inhibition by vardenafil as a novel treatment of portal hypertension in patients with cirrhosis.In the herein presented'letter to the editor',the administration of tadalafil did not influence portal haemodynamics but impaired systemic haemodynamics in patients with cirrhosis.Our observations concur with the results of a report in a previous issue of World Journal of Gastroenterology(October 2008).Moreover,tadalafil adversely affected renal function in patients with decompensated liver disease.
作者 Georgios N Kalambokis Paraskevi Kosta Konstantinos Pappas Epameinondas V Tsianos
机构地区 [ Department of Radiology Department of Cardiology
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2010年第39期5009-5010,共2页 世界胃肠病学杂志（英文版）
关键词 TADALAFIL Portal hypertension CIRRHOSIS ASCITES Phosphodiesterase-5 inhibition Tadalafil Portal hypertension Cirrhosis Ascites Phosphodiesterase-5 inhibition
分类号 R575.2 [医药卫生—消化系统]
  • 相关文献

参考文献6

  • 1Jens Otto Clemmesen,Annamaria Giraldi,Peter Ott,Kim Dalhoff,Bent Adel Hansen,Fin Stolze Larsen.Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis[J].World Journal of Gastroenterology,2008,14(40):6208-6212. 被引量：2
  • 2Tandon P,Inayat I,Tal M,Spector M,Shea M,Groszmann RJ,Garcia-Tsao G.Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis. Clinics in Gastroenterology . 2010
  • 3Lee KC,Yang YY,Wang YW,Hou MC,Lee FY,Lin HC,Lee SD.Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients. Hepatology Research . 2008
  • 4Carson CC,,Rajfer J,Eardley I,Carrier S,Denne JS, et al.The efficacy and safety of tadalafil: an update. BJU International . 2004
  • 5Deibert P,Schumacher YO,Ruecker G,Opitz OG,Blum HE,Rossle M,Kreisel W.Effect of vardenafil,an inhibitor of phosphodiesterase-5,on portal haemodynamics in normal and cirrhotic liver --results of a pilot study. Alimentary Pharmacology and Therapeutics . 2006
  • 6Thiesson HC,Jensen BL,Jespersen B,Schaffalitzky de Muckadell OB,Bistrup C,Walter S,Ottosen PD,Veje A,Skott O.Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. American Journal of Physiology Renal Physiology . 2005

二级参考文献26

  • 1[1]Cornely CM,Schade RR,Van Thiel DH,Gavaler JS.Chronic advanced liver disease and impotence:cause and effect? Hepatology 1984; 4:1227-1230
  • 2[2]Jensen SB,Gluud C.Sexual dysfunction in men with alcoholic liver cirrhosis.A comparative study.Liver 1985; 5:94-100
  • 3[3]Lebrec D,Nouel O,Corbic M,Benhamou JP.Propranolol-a medical treatment for portal hypertension? Lancet 1980; 2:180-182
  • 4[4]Grnszmann RJ,Bosch J,Grace ND,Conn HO,Garcia-Tsao G,Navasa M,Alberts J,Rodes J,Fischer R,Bermann M.Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage.Gastroenterology 1990; 99:1401-1407
  • 5[5]Burris JF,Goldstein J,Zager PG,Sutton JM,Sirgo MA,Plachetka JR.Comparative tolerability of labetalol versus propranolol,atenolol,pindolol,metoprolol,and nadolol.J Clin Hypertens 1986; 2:285-293
  • 6[6]Boolell M,Gepi-Attee S,Gingell JC,Allen MJ.Sildenafil,a novel effective oral therapy for male erectile dysfunction.Br J Urol 1996; 78:257-261
  • 7[7]Goldstein I,Lue TF,Padma-Nathan H,Rosen RC,Steers WD,Wicker PA.Oral sildenafil in the treatment of erectile dysfunction.Sildenafil Study Group.N Engl J Med 1998; 338:1397-1404
  • 8[8]Corbin JD,Francis SH.Cyclic GMP phosphodiesterase-5:target of sildenafil.J Biol Chem 1999; 274:13729-13732
  • 9[9]Sampson LJ,Hinton JM,Garland CJ.Evidence for expression and function of phosphodiesterase type 5 (PDE-V) in rat resistance arteries.Br J Pharmacol 2001; 132:13-17
  • 10[10]Colle I,De Vriese AS,Van Vlierberghe H,Lameire NH,DeVos M.Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients.Liver Int 2004; 24:63-68

共引文献1

World Journal of Gastroenterology
2010年 第39期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部